ASCO 2022 | Current role of MRD in AML

Name: Current role of MRD in AML
Uploaded: 2022-06-04T00:00:00Z
Duration: 1 min 11 s
Description: Christopher Hourigan, MD, DPhil, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, provides an overview of the current role of measurable residual disease (MRD) testing in patients with acute myeloid leukemia (AML). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Christopher Hourigan • 4 Jun 2022

ASCO 2022

Acute Myeloid Leukemia Leukemia

Christopher Hourigan, MD, DPhil, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, provides an overview of the current role of measurable residual disease (MRD) testing in patients with acute myeloid leukemia (AML). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.